[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335731-105":59,"doc-detail-335731-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","68-ga-my6349-petct-imaging-to-assess-trop2-expression-in-multiple-types-of-cancer","68 Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer","","68Ga-MY6349 PET/CT was developed as a Trop2-specific radiotracer to address the clinical need for accurate evaluation of Trop2 expression across human epithelial cancers. A prospective translational study enrolled 90 patients with 15 cancer types, including paired imaging with 18F-FDG or, for prostate cancer, 68Ga-PSMA-11. Uptake of 68Ga-MY6349 was generally high yet heterogeneous, correlating with immunohistochemistry-defined Trop2 levels at primary and metastatic sites. In selected cancers, 68Ga-MY6349 showed higher tumor uptake than 18F-FDG and improved tumor-to-background contrast versus 68Ga-PSMA-11 for prostate cancer, enabling visualization of more metastatic lesions, supporting diagnosis, staging, and guidance for Trop2-targeted therapies.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/68-ga-my6349-petct-imaging-to-assess-trop2-expression-in-multiple-types-of-cancer/335731/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/68-ga-my6349-petct-imaging-to-assess-trop2-expression-in-multiple-types-of-cancer/335731.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of using 68Ga-MY6349 PET/CT in this study?","Question",{"text":112,"@type":113},"To assess Trop2 expression in tumors across multiple cancer types by using a Trop2-specific radiotracer, supporting diagnosis, staging, and treatment decisions for Trop2-targeted therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study designed and how many patients were included?",{"text":117,"@type":113},"The prospective translational study enrolled 90 patients across 15 types of cancer who underwent 68Ga-MY6349 PET/CT, including paired comparisons with 18F-FDG in 78 patients and with 68Ga-PSMA-11 in 12 prostate-cancer patients.",{"name":119,"@type":110,"acceptedAnswer":120},"How did 68Ga-MY6349 uptake relate to Trop2 expression levels?",{"text":121,"@type":113},"Tumor uptake of 68Ga-MY6349 was generally high but heterogeneous, and Trop2 expression measured by immunohistochemistry showed a high correlation with 68Ga-MY6349 uptake at primary and metastatic tumor sites.",{"name":123,"@type":110,"acceptedAnswer":124},"What were the key comparative imaging results with 18F-FDG and 68Ga-PSMA-11?",{"text":125,"@type":113},"For certain cancers (breast, prostate, and thyroid), 68Ga-MY6349 demonstrated higher tumor uptake than 18F-FDG. In prostate cancer, 68Ga-MY6349 showed comparable lesion uptake to 68Ga-PSMA-11 but better tumor-to-background contrast, helping visualize more metastatic lesions.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},335731,1790169127,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":4},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","The Journal of Clinical Investigation CLINICAL RESEAR CH AND PUBLIC HEALTH  \n68 Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer  \nHaojun Chen,1,2 Liang Zhao,1,3,4 Yizhen Pang,1,3,4 Jiyun Shi,5 Hannan Gao,5 Yining Sun,5 Jianhao Chen,1 Hao Fu,1 Jiayu Cai,1 Lingyu Yu,1 Ru Zeng,6 Long Sun,1 Hua Wu,1 Zhanxiang Wang,7 and Fan Wang5,8,9  \n1Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. 2Xiamen Key Laboratory of Rare Earth Photoelectric Functional Materials, Xiamen Institute of Rare Earth Materials, Haixi Institute, Chinese Academy of Sciences, Xiamen, China. 3Departments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore. 4Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 5Key Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. 6Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China. 7Department of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. 8Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, China. 9Guangzhou National Laboratory, Guangzhou, China.  \nBACKGROUND. Considering that trophoblast cell-surface antigen 2 (Trop2) is overexpressed in a wide range of human epithelial cancers, it presents an attractive target for diagnosis and treatment of multiple types of cancer. Herein, we have developed a Trop2-specific radiotracer, 68Ga-MY6349, and present a prospective, investigator-initiated trial to explore the clinical value of 68Ga-MY6349 PET/CT.  \nMETHODS. In this translational study, 90 patients with 15 types of cancer who underwent 68Ga-MY6349 PET/CT were enrolled prospectively. Among them, 78 patients underwent paired 68Ga-MY6349 and 18F-FDG PET/CT, and 12 patients with prostate cancer underwent paired 68Ga-MY6349 and 68Ga-PSMA-11 PET/CT.  \nRESULTS. Among the 90 patients across 15 types of cancer, 68Ga-MY6349 uptake in tumors was generally high but heterogeneous, varying among lesions, patients, and cancer types. Trop2 expression level determined by immunohistochemistry was highly correlated with 68Ga-MY6349 uptake at primary and metastatic tumor sites. 68Ga-MY6349 PET/CT showed higher tumor uptake (quantified by maximum standardized uptake value) than 18F-FDG PET/CT in certain types of cancer, including breast (7.2 vs. 5.4, P \u003C 0.001), prostate (9.2 vs. 3.0, P \u003C 0.001), and thyroid cancers (8.5 vs. 3.7, P \u003C 0.001). Compared with 68Ga-PSMA-11, 68Ga-MY6349 PET/CT exhibited comparable lesion uptake (12.2 vs. 12.5, P = 0.223) but a better tumor-to-background contrast (15.8 vs. 12.2, P \u003C 0.001) for primary and metastatic prostate cancer, allowing visualization of more metastatic lesions.  \nCONCLUSION. 68Ga-MY6349 PET/CT is a noninvasive method for comprehensively assessing Trop2 expression in tumors, which can improve diagnosis and staging for cancer patients and aid in decision making for Trop2-targeted therapies and advancing of personalized treatment.  \nTRIAL REGISTRATION. ClinicalTrials.gov NCT06188468 .  \nFUNDING. National Natural Science Foundation of China, National Key R&D Program of China, Nuclear Energy R&D project, Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare, Key Scientific ","cbCaifTWrrQIjxzQ","https://ap.wps.com/l/cbCaifTWrrQIjxzQ","pdf",18308648,14,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Trial Registration and Funding\n# Introduction","[{\"question\":\"What is the purpose of using 68Ga-MY6349 PET/CT in this study?\",\"answer\":\"To assess Trop2 expression in tumors across multiple cancer types by using a Trop2-specific radiotracer, supporting diagnosis, staging, and treatment decisions for Trop2-targeted therapies.\"},{\"question\":\"How was the study designed and how many patients were included?\",\"answer\":\"The prospective translational study enrolled 90 patients across 15 types of cancer who underwent 68Ga-MY6349 PET/CT, including paired comparisons with 18F-FDG in 78 patients and with 68Ga-PSMA-11 in 12 prostate-cancer patients.\"},{\"question\":\"How did 68Ga-MY6349 uptake relate to Trop2 expression levels?\",\"answer\":\"Tumor uptake of 68Ga-MY6349 was generally high but heterogeneous, and Trop2 expression measured by immunohistochemistry showed a high correlation with 68Ga-MY6349 uptake at primary and metastatic tumor sites.\"},{\"question\":\"What were the key comparative imaging results with 18F-FDG and 68Ga-PSMA-11?\",\"answer\":\"For certain cancers (breast, prostate, and thyroid), 68Ga-MY6349 demonstrated higher tumor uptake than 18F-FDG. In prostate cancer, 68Ga-MY6349 showed comparable lesion uptake to 68Ga-PSMA-11 but better tumor-to-background contrast, helping visualize more metastatic lesions.\"}]","68 Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer | PDF",1790012140,35]